BRIEF — Omeros Corporation To Terminate Yartemlea Compassionate — Use Program In Europe Due To US Demand
Oct 16 (Reuters) — Omeros Corporation: Omeros Corporation Receives Chmp Negative Opinion Following Re-examination Of European Marketing Authorization Application For Narsoplimab In Ta-tma Omeros Corporation - To Terminate Yartemlea Compassionate-use Program In Europe Due To U.s. Demand Omeros Corporation - Plans Clinic